Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism
Identifieur interne : 000211 ( PascalFrancis/Corpus ); précédent : 000210; suivant : 000212Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism
Auteurs : Connie Marras ; Andrea Gruneir ; Paula Rochon ; XUESONG WANG ; Geoff Anderson ; Jonathan Brotchie ; Chaim M. Bell ; Susan Fox ; Peter C. AustinSource :
- Annals of neurology [ 0364-5134 ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Objective: A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism. Methods: Data were obtained from Ontario's health care administrative databases. Within a cohort of hypertensive individuals older than 65 years who developed parkinsonism, we examined the effect of the length of exposure to less brain-penetrant dihydropyridines (amlodipine) and more brain-penetrant dihydropyridines (eg, nifedipine, felodipine) on parkinsonism milestones as measured by time to requiring drug treatment for parkinsonism, nursing home admission, and death. Results: Among 4,733 hypertensive individuals with parkinsonism, longer treatment with any dihydropyridine was associated with a decreased risk of each of the 3 outcomes. There was no difference, however, between amlodipine (adjusted hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.42-0.50 for initiation of drug treatment; HR, 0.68; 95% CI, 0.63-0.73 for application for nursing home admission; and HR, 0.75; 95% CI, 0.70-0.80 for death) and nonamlodipine dihydropyridines (adjusted HRs [95% Cls], 0.45 [0.39-0.53], 0.74 [0.67-0.81], and 0.74 [0.64-0.85] for the 3 milestones, respectively). Interpretation: We found no specific beneficial effect of treatment with brain-penetrant dihydropyridines on delaying parkinsonism progression milestones. Dihydropyridine calcium channel blockers are unlikely to have a clinically significant effect on the course of parkinsonism, particularly Parkinson disease, in the doses used to treat hypertension.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 12-0170080 INIST |
|---|---|
| ET : | Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism |
| AU : | MARRAS (Connie); GRUNEIR (Andrea); ROCHON (Paula); XUESONG WANG; ANDERSON (Geoff); BROTCHIE (Jonathan); BELL (Chaim M.); FOX (Susan); AUSTIN (Peter C.) |
| AF : | Division of Neurology, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut., 8 aut.); University of Toronto/Toronto, Ontario/Canada (1 aut., 3 aut., 7 aut., 8 aut.); Women's College Hospital and Women's College Research Institute/Toronto, Ontario/Canada (2 aut., 3 aut.); Institute for Clinical Evaluative Sciences/Toronto, Ontario/Canada (2 aut., 3 aut., 4 aut., 5 aut., 9 aut.); Toronto Western Research Institute/Toronto, Ontario/Canada (6 aut.); Keenan Research Centre in the Li Ka Shing Knowledge Institute at St. Michael's Hospital/Toronto, Ontario/Canada (7 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2012; Vol. 71; No. 3; Pp. 362-369; Bibl. 18 ref. |
| LA : | Anglais |
| EA : | Objective: A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism. Methods: Data were obtained from Ontario's health care administrative databases. Within a cohort of hypertensive individuals older than 65 years who developed parkinsonism, we examined the effect of the length of exposure to less brain-penetrant dihydropyridines (amlodipine) and more brain-penetrant dihydropyridines (eg, nifedipine, felodipine) on parkinsonism milestones as measured by time to requiring drug treatment for parkinsonism, nursing home admission, and death. Results: Among 4,733 hypertensive individuals with parkinsonism, longer treatment with any dihydropyridine was associated with a decreased risk of each of the 3 outcomes. There was no difference, however, between amlodipine (adjusted hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.42-0.50 for initiation of drug treatment; HR, 0.68; 95% CI, 0.63-0.73 for application for nursing home admission; and HR, 0.75; 95% CI, 0.70-0.80 for death) and nonamlodipine dihydropyridines (adjusted HRs [95% Cls], 0.45 [0.39-0.53], 0.74 [0.67-0.81], and 0.74 [0.64-0.85] for the 3 milestones, respectively). Interpretation: We found no specific beneficial effect of treatment with brain-penetrant dihydropyridines on delaying parkinsonism progression milestones. Dihydropyridine calcium channel blockers are unlikely to have a clinically significant effect on the course of parkinsonism, particularly Parkinson disease, in the doses used to treat hypertension. |
| CC : | 002B17; 002B17G |
| FD : | Parkinsonisme; Pathologie du système nerveux; Antagoniste calcium |
| ED : | Parkinsonism; Nervous system diseases; Calcium antagonist |
| SD : | Parkinson síndrome; Sistema nervioso patología; Antagonista calcio |
| LO : | INIST-16555.354000509774390100 |
| ID : | 12-0170080 |
Links to Exploration step
Pascal:12-0170080Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><inist:fA14 i1="01"><s1>Division of Neurology, Toronto Western Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gruneir, Andrea" sort="Gruneir, Andrea" uniqKey="Gruneir A" first="Andrea" last="Gruneir">Andrea Gruneir</name><affiliation><inist:fA14 i1="03"><s1>Women's College Hospital and Women's College Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rochon, Paula" sort="Rochon, Paula" uniqKey="Rochon P" first="Paula" last="Rochon">Paula Rochon</name><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Women's College Hospital and Women's College Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Xuesong Wang" sort="Xuesong Wang" uniqKey="Xuesong Wang" last="Xuesong Wang">XUESONG WANG</name><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anderson, Geoff" sort="Anderson, Geoff" uniqKey="Anderson G" first="Geoff" last="Anderson">Geoff Anderson</name><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name><affiliation><inist:fA14 i1="05"><s1>Toronto Western Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M." last="Bell">Chaim M. Bell</name><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="06"><s1>Keenan Research Centre in the Li Ka Shing Knowledge Institute at St. Michael's Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name><affiliation><inist:fA14 i1="01"><s1>Division of Neurology, Toronto Western Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Austin, Peter C" sort="Austin, Peter C" uniqKey="Austin P" first="Peter C." last="Austin">Peter C. Austin</name><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0170080</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0170080 INIST</idno><idno type="RBID">Pascal:12-0170080</idno><idno type="wicri:Area/PascalFrancis/Corpus">000211</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><inist:fA14 i1="01"><s1>Division of Neurology, Toronto Western Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gruneir, Andrea" sort="Gruneir, Andrea" uniqKey="Gruneir A" first="Andrea" last="Gruneir">Andrea Gruneir</name><affiliation><inist:fA14 i1="03"><s1>Women's College Hospital and Women's College Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rochon, Paula" sort="Rochon, Paula" uniqKey="Rochon P" first="Paula" last="Rochon">Paula Rochon</name><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Women's College Hospital and Women's College Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Xuesong Wang" sort="Xuesong Wang" uniqKey="Xuesong Wang" last="Xuesong Wang">XUESONG WANG</name><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anderson, Geoff" sort="Anderson, Geoff" uniqKey="Anderson G" first="Geoff" last="Anderson">Geoff Anderson</name><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name><affiliation><inist:fA14 i1="05"><s1>Toronto Western Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M." last="Bell">Chaim M. Bell</name><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="06"><s1>Keenan Research Centre in the Li Ka Shing Knowledge Institute at St. Michael's Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name><affiliation><inist:fA14 i1="01"><s1>Division of Neurology, Toronto Western Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Austin, Peter C" sort="Austin, Peter C" uniqKey="Austin P" first="Peter C." last="Austin">Peter C. Austin</name><affiliation><inist:fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Calcium antagonist</term><term>Nervous system diseases</term><term>Parkinsonism</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term><term>Pathologie du système nerveux</term><term>Antagoniste calcium</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism. Methods: Data were obtained from Ontario's health care administrative databases. Within a cohort of hypertensive individuals older than 65 years who developed parkinsonism, we examined the effect of the length of exposure to less brain-penetrant dihydropyridines (amlodipine) and more brain-penetrant dihydropyridines (eg, nifedipine, felodipine) on parkinsonism milestones as measured by time to requiring drug treatment for parkinsonism, nursing home admission, and death. Results: Among 4,733 hypertensive individuals with parkinsonism, longer treatment with any dihydropyridine was associated with a decreased risk of each of the 3 outcomes. There was no difference, however, between amlodipine (adjusted hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.42-0.50 for initiation of drug treatment; HR, 0.68; 95% CI, 0.63-0.73 for application for nursing home admission; and HR, 0.75; 95% CI, 0.70-0.80 for death) and nonamlodipine dihydropyridines (adjusted HRs [95% Cls], 0.45 [0.39-0.53], 0.74 [0.67-0.81], and 0.74 [0.64-0.85] for the 3 milestones, respectively). Interpretation: We found no specific beneficial effect of treatment with brain-penetrant dihydropyridines on delaying parkinsonism progression milestones. Dihydropyridine calcium channel blockers are unlikely to have a clinically significant effect on the course of parkinsonism, particularly Parkinson disease, in the doses used to treat hypertension.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0></fA01><fA02 i1="01"><s0>ANNED3</s0></fA02><fA03 i2="1"><s0>Ann. neurol.</s0></fA03><fA05><s2>71</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism</s1></fA08><fA11 i1="01" i2="1"><s1>MARRAS (Connie)</s1></fA11><fA11 i1="02" i2="1"><s1>GRUNEIR (Andrea)</s1></fA11><fA11 i1="03" i2="1"><s1>ROCHON (Paula)</s1></fA11><fA11 i1="04" i2="1"><s1>XUESONG WANG</s1></fA11><fA11 i1="05" i2="1"><s1>ANDERSON (Geoff)</s1></fA11><fA11 i1="06" i2="1"><s1>BROTCHIE (Jonathan)</s1></fA11><fA11 i1="07" i2="1"><s1>BELL (Chaim M.)</s1></fA11><fA11 i1="08" i2="1"><s1>FOX (Susan)</s1></fA11><fA11 i1="09" i2="1"><s1>AUSTIN (Peter C.)</s1></fA11><fA14 i1="01"><s1>Division of Neurology, Toronto Western Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="03"><s1>Women's College Hospital and Women's College Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="05"><s1>Toronto Western Research Institute</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>Keenan Research Centre in the Li Ka Shing Knowledge Institute at St. Michael's Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>7 aut.</sZ></fA14><fA20><s1>362-369</s1></fA20><fA21><s1>2012</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>16555</s2><s5>354000509774390100</s5></fA43><fA44><s0>0000</s0><s1>© 2012 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>18 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>12-0170080</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of neurology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Objective: A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism. Methods: Data were obtained from Ontario's health care administrative databases. Within a cohort of hypertensive individuals older than 65 years who developed parkinsonism, we examined the effect of the length of exposure to less brain-penetrant dihydropyridines (amlodipine) and more brain-penetrant dihydropyridines (eg, nifedipine, felodipine) on parkinsonism milestones as measured by time to requiring drug treatment for parkinsonism, nursing home admission, and death. Results: Among 4,733 hypertensive individuals with parkinsonism, longer treatment with any dihydropyridine was associated with a decreased risk of each of the 3 outcomes. There was no difference, however, between amlodipine (adjusted hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.42-0.50 for initiation of drug treatment; HR, 0.68; 95% CI, 0.63-0.73 for application for nursing home admission; and HR, 0.75; 95% CI, 0.70-0.80 for death) and nonamlodipine dihydropyridines (adjusted HRs [95% Cls], 0.45 [0.39-0.53], 0.74 [0.67-0.81], and 0.74 [0.64-0.85] for the 3 milestones, respectively). Interpretation: We found no specific beneficial effect of treatment with brain-penetrant dihydropyridines on delaying parkinsonism progression milestones. Dihydropyridine calcium channel blockers are unlikely to have a clinically significant effect on the course of parkinsonism, particularly Parkinson disease, in the doses used to treat hypertension.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Antagoniste calcium</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Calcium antagonist</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Antagonista calcio</s0><s5>09</s5></fC03><fN21><s1>129</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 12-0170080 INIST</NO><ET>Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism</ET><AU>MARRAS (Connie); GRUNEIR (Andrea); ROCHON (Paula); XUESONG WANG; ANDERSON (Geoff); BROTCHIE (Jonathan); BELL (Chaim M.); FOX (Susan); AUSTIN (Peter C.)</AU><AF>Division of Neurology, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut., 8 aut.); University of Toronto/Toronto, Ontario/Canada (1 aut., 3 aut., 7 aut., 8 aut.); Women's College Hospital and Women's College Research Institute/Toronto, Ontario/Canada (2 aut., 3 aut.); Institute for Clinical Evaluative Sciences/Toronto, Ontario/Canada (2 aut., 3 aut., 4 aut., 5 aut., 9 aut.); Toronto Western Research Institute/Toronto, Ontario/Canada (6 aut.); Keenan Research Centre in the Li Ka Shing Knowledge Institute at St. Michael's Hospital/Toronto, Ontario/Canada (7 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2012; Vol. 71; No. 3; Pp. 362-369; Bibl. 18 ref.</SO><LA>Anglais</LA><EA>Objective: A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism. Methods: Data were obtained from Ontario's health care administrative databases. Within a cohort of hypertensive individuals older than 65 years who developed parkinsonism, we examined the effect of the length of exposure to less brain-penetrant dihydropyridines (amlodipine) and more brain-penetrant dihydropyridines (eg, nifedipine, felodipine) on parkinsonism milestones as measured by time to requiring drug treatment for parkinsonism, nursing home admission, and death. Results: Among 4,733 hypertensive individuals with parkinsonism, longer treatment with any dihydropyridine was associated with a decreased risk of each of the 3 outcomes. There was no difference, however, between amlodipine (adjusted hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.42-0.50 for initiation of drug treatment; HR, 0.68; 95% CI, 0.63-0.73 for application for nursing home admission; and HR, 0.75; 95% CI, 0.70-0.80 for death) and nonamlodipine dihydropyridines (adjusted HRs [95% Cls], 0.45 [0.39-0.53], 0.74 [0.67-0.81], and 0.74 [0.64-0.85] for the 3 milestones, respectively). Interpretation: We found no specific beneficial effect of treatment with brain-penetrant dihydropyridines on delaying parkinsonism progression milestones. Dihydropyridine calcium channel blockers are unlikely to have a clinically significant effect on the course of parkinsonism, particularly Parkinson disease, in the doses used to treat hypertension.</EA><CC>002B17; 002B17G</CC><FD>Parkinsonisme; Pathologie du système nerveux; Antagoniste calcium</FD><ED>Parkinsonism; Nervous system diseases; Calcium antagonist</ED><SD>Parkinson síndrome; Sistema nervioso patología; Antagonista calcio</SD><LO>INIST-16555.354000509774390100</LO><ID>12-0170080</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000211 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000211 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:12-0170080
|texte= Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism
}}
| This area was generated with Dilib version V0.6.29. |  |